{"filing":{"accession_number":"0001213900-26-099002","cik":"0001894525","ticker":"APUS","company_name":"Apimeds Pharmaceuticals US, Inc.","form":"8-K","filing_date":"2026-09-11","report_date":"2026-09-10","primary_document":"ea0305245-8k_apimeds.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1894525/000121390026099002/ea0305245-8k_apimeds.htm"},"events":[{"id":32846,"run_id":30199,"accession_number":"0001213900-26-099002","anchor_item_number":"1.01","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The Company entered into an Amendment that restructures the composition of the Board of Directors, specifying board size, member names, and removal restrictions tied to consent from Dr. Vin Menon and the Inscobee Parties, arising from a settlement agreement.","company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","filing_date":"2026-09-11","form":"8-K","submitted_at":null,"items":[{"id":36122,"accession_number":"0001213900-26-099002","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The Amendment restructures the composition of the Company's board of directors, specifying board size, member names, and removal restrictions tied to consent from Dr. Vin Menon and the Inscobee Parties. While this is a governance event involving board composition, it does not fit the specific categories of exec_appointment, exec_departure, or exec_compensation—it is a structural governance arrangement arising from a settlement agreement. This is material as it affects control and governance of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T13:11:53.612326+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":32847,"run_id":30199,"accession_number":"0001213900-26-099002","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Sungjoon Chae was appointed to the Board of Directors effective September 10, 2026, pursuant to a Settlement Agreement. Chae has been serving as Co-Chief Executive Officer since May 2026.","company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","filing_date":"2026-09-11","form":"8-K","submitted_at":null,"items":[{"id":36123,"accession_number":"0001213900-26-099002","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Sungjoon Chae was appointed to the Board of Directors effective September 10, 2026, pursuant to a Settlement Agreement. The disclosure explicitly states the Board \"appointed Sungjoon Chae to serve as a member of the Board.\" This is a clear executive appointment event. The appointment is material because it represents a change in board composition and governance structure, and notably Chae has already been serving as Co-Chief Executive Officer since May 2026, making his board appointment significant to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T13:11:53.612326+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36122,"accession_number":"0001213900-26-099002","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"governance_other","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The Amendment restructures the composition of the Company's board of directors, specifying board size, member names, and removal restrictions tied to consent from Dr. Vin Menon and the Inscobee Parties. While this is a governance event involving board composition, it does not fit the specific categories of exec_appointment, exec_departure, or exec_compensation—it is a structural governance arrangement arising from a settlement agreement. This is material as it affects control and governance of the registrant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T13:11:53.612326+00:00","company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","filing_date":"2026-09-11"},{"id":36123,"accession_number":"0001213900-26-099002","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Sungjoon Chae was appointed to the Board of Directors effective September 10, 2026, pursuant to a Settlement Agreement. The disclosure explicitly states the Board \"appointed Sungjoon Chae to serve as a member of the Board.\" This is a clear executive appointment event. The appointment is material because it represents a change in board composition and governance structure, and notably Chae has already been serving as Co-Chief Executive Officer since May 2026, making his board appointment significant to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T13:11:53.612326+00:00","company_name":"Apimeds Pharmaceuticals US, Inc.","ticker":"APUS","filing_date":"2026-09-11"}]}